Dr. John H. Sampson discusses rindopepimut elimiting brain tumor cells that express the epidermal growth factor receptor mutation variant III (EGFRvIII).
John H. Sampson, MD, PhD, MBA, MHSc
Advertisement
Articles by John H. Sampson, MD, PhD, MBA, MHSc
Advertisement
Latest Updated Articles
Dr. John H. Sampson on the Use of Rindopepimut in Brain CancerPublished: November 25th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
